News

SCF Technologies, LLC and CritiTech, Inc. Announce NIH/NCI Grant

April 24, 2009

FOR IMMEDIATE RELEASE

LAWRENCE , Kansas- Today, Sam Campbell , President of SCF Technologies, LLC, an affiliate of CritiTech, Inc. announced that SCF Technologies, LLC was awarded a SBIR Phase I grant from the National Institute of Health/National Cancer Institute. The funded project involves the use of supercritical carbon dioxide for drying and sterilizing parenteral dosage forms of drug product. This project proposes a new technique to safely dry and terminally sterilize drugs in their dispensing containers. If successful, this approach will lead to simpler processing of injectable drugs that would increase safety and lower production costs. The work on this project will take place at in space leased from CritiTech, Inc by SCF Technologies, LLC at 4950 Research Parkway, Lawrence, Kansas.

Many drugs, including anticancer agents, must be administered by non-oral routes (intravenous or intraperitoneal) and therefore must be sterile for injection. For stability reasons such drugs must be dry as well as sterile. Current technology requires a two-step process of filter-sterilization followed by lyophilization under aseptic conditions to achieve safe, stable dosage forms. SCF Technologies, LLC through this project intends to demonstrate the capability of safely drying and sterilizing drugs in their dispensing containers in a single process.

The principal investigator on the grant is Dr. Charles J. Decedue, Vice President of Research and Development for SCF Technologies, LLC and Sr. Research Fellow for CritiTech, Inc. Dr. Decedue was formerly the Executive Director of the Higuchi Biosciences Center , at the University of Kansas . Decedue said, We are excited to get started on this Proof-of-Concept project. If successful, this research could lead to substantial improvements in drug processing and significant growth for CritiTech.

SCF Technologies, LLC is a research and development company focused on the applications of supercritical fluid technology in the pharmaceutical industry. Much of the companys R & D efforts are based on a technology development license granted to them by CritiTech, Inc. CritiTech, Inc. was founded on ground breaking research in Supercritical Fluid technology conducted by Dr. Bala Subramaniam at the Kansas University School of Engineering. CritiTech has continued to expand its efforts using this technology in critical drug delivery and development technology for the pharmaceutical industry. CritiTech has several drugs under development. CritiTechs first drug, Nanotax®, is in phase I human trials at the University of Kansas Cancer Center in Kansas City for the treatment of ovarian and other intraperitoneal cancers.